Sign Out
Use during Pregnancy, Delivery or Lactation: (1) Pregnant or possibly pregnant women should receive DAYVIGO only when the benefit of treatment is considered to outweigh the risks. (Safety of use during pregnancy has not been established.)
(2) Avoid treating lactating women with DAYVIGO. When there is no other choice but to administer the drug, instruct them to stop breastfeeding. (Lemborexant and its metabolites transfer to breast milk in lactating rats.)
